Bull case
Telix Pharmaceuticals is viewed positively because its core Illuccix franchise is being augmented by multiple high-value growth drivers, including Pixclara’s FDA approval for glioma imaging and ITM-11’s strong COMPETE data, where median PFS improved to 23.9 months versus 14.1 months with everolimus and grade 3/4 treatment-related adverse events were lower at 18% versus 40%. The company’s isotope supply platform adds a scalable, profitable revenue stream, generating $273MM in 2025 revenue with ~40% CAGR from 2021–2025 and reaching >65 countries, while also reducing dependence on external suppliers for future commercial demand. Financially, ITM produced $156MM of revenue in 1H26 with manufacturing gross margins above 40%, expected annualized 2026 EBITDA of about $106MM, and pro forma cash of roughly $325MM as of June 30, 2026, supporting broader pipeline investment.